Clinical Trials
37 trialsNeoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
ALICE
Oslo University Hospital
ICON
Oslo University Hospital
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Spanish Breast Cancer Research Group
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
Spanish Breast Cancer Research Group
Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
Columbia University
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
West Virginia University
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stop&Go
Borstkanker Onderzoek Groep
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)
Merck Sharp & Dohme LLC
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Opti-HER
SOLTI Breast Cancer Research Group
CAPRICE
SOLTI Breast Cancer Research Group
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
University of Washington
Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer
Hebei Medical University Fourth Hospital
The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)
Merck Sharp & Dohme LLC
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
Merck Sharp & Dohme LLC
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
US Oncology Research
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
University of Alabama at Birmingham
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
National Cancer Institute (NCI)
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Caelyx Adjuvant in Elderly Breast Cancer
Universitaire Ziekenhuizen KU Leuven
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
Merck Sharp & Dohme LLC
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Northwestern University
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
SCRI Development Innovations, LLC
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
Herlev Hospital
Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP